Lixte Biotechnology Holdings, Inc.
LIXT
$5.16
$0.122.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.45% | -155.30% | -9.32% | -14.88% | 37.35% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.93% | 274.70% | 168.81% | 27.82% | -26.97% |
| Change in Net Operating Assets | 511.13% | 144.55% | -51.09% | 170.00% | 24.74% |
| Cash from Operations | -17.38% | -90.11% | 14.25% | 5.04% | 37.48% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 83.32% | -- | -- | -- | -- |
| Cash from Investing | 79.71% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -15.14% | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -8,818.00% | 200.00% | -- | -- | -- |
| Cash from Financing | -30.96% | 55,748.00% | -101.09% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.91% | 502.15% | -243.91% | 157.74% | 37.48% |